Hypothesis-Driven, Structure-Based Design in Photopharmacology: The Case of eDHFR Inhibitors

Piermichele Kobauri, Nicole S Galenkamp, Albert M Schulte, Jisk de Vries, Nadja A Simeth, Giovanni Maglia, Sebastian Thallmair, Dušan Kolarski, Wiktor Szymanski*, Ben L Feringa*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)
295 Downloads (Pure)

Abstract

Photopharmacology uses light to regulate the biological activity of drugs. This precise control is obtained through the incorporation of molecular photoswitches into bioactive molecules. A major challenge for photopharmacology is the rational design of photoswitchable drugs that show light-induced activation. Computer-aided drug design is an attractive approach toward more effective, targeted design. Herein, we critically evaluated different structure-based approaches for photopharmacology with Escherichia coli dihydrofolate reductase (eDHFR) as a case study. Through the iterative examination of our hypotheses, we progressively tuned the design of azobenzene-based, photoswitchable eDHFR inhibitors in five design-make-switch-test-analyze cycles. Targeting a hydrophobic subpocket of the enzyme and a specific salt bridge only with the thermally metastable cis-isomer emerged as the most promising design strategy. We identified three inhibitors that could be activated upon irradiation and reached potencies in the low-nanomolar range. Above all, this systematic study provided valuable insights for future endeavors toward rational photopharmacology.

Original languageEnglish
Article number1c01962
Pages (from-to)4798-4817
Number of pages20
JournalJournal of Medicinal Chemistry
Volume65
Issue number6
Early online date2022
DOIs
Publication statusPublished - 24-Mar-2022

Fingerprint

Dive into the research topics of 'Hypothesis-Driven, Structure-Based Design in Photopharmacology: The Case of eDHFR Inhibitors'. Together they form a unique fingerprint.

Cite this